CRDF Gains 39.59%

CRDF (CRDF:NASDAQ) soared at $8.11, a gain of 39.6%. The stock got featured on our News Catalysts scanner on Thu 17 Sep 20 at 08:17 AM in the 'BIOTECH' category. From Wed 02 Sep 20, the stock recorded 22.22% Up Days and 20.00% Green Days

The share price of the company has been moving sideways in recent weeks.

About CRDF (CRDF:NASDAQ)

Cardiff Oncology Inc is a clinical-stage oncology therapeutics company, developing onvansertib, a first-in-class, 3rd generation, oral and highly-selectivePolo-like Kinase 1 (PLK1) inhibitor to treat patients with leukemia, lymphoma and solid tumor cancers. The company is making advancements in its clinical development program, with three ongoingclinical trials: a Phase 1b/2 trial in Acute Myeloid Leukemia (AML); aPhase 2 trial in metastatic Castration-Resistant Prostate Cancer (mCRPC)and a Phase 1b/2 trial in metastatic Colorectal Cancer (mCRC). The firm's treatment includes KRAS-mutated metastatic colorectal cancer (mCRC), metastatic castrate-resistant prostate cancer (mCRPC) and acute myeloid leukemia (AML).